3-NAntC displayed superior anti-tumor activity in vitro compared to cisplatin and comparable activity to doxorubicin with more favorable tolerability.
3-NAntC displayed superior anti-tumor activity in vitro compared to cisplatin and comparable activity to doxorubicin with more favorable tolerability.